

AKERS BIOSCIENCES, INC.

OVERVIEW

Akers Biosciences, Inc. ("ABI or Company") develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the patient or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major pharmaceutical companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

The use of rapid tests which can be performed at the point of care when and where the patient is being consulted can result in immediate treatment regimens, and is an important development in the practice of medicine. Point of care testing addresses today's challenges in the healthcare industry, such as:

- Cost pressures/efficiency of healthcare delivery.
- Need for tools for pharmaceutical companies to monitor side effects of medicines/new agents in development.
- Need for affordable mass screening tests for key infectious diseases, cardiac conditions, and metabolic markers.
- Public health needs in developing countries lacking basic health infrastructure.

TECHNOLOGIES

All of the Company's proprietary technologies provide the platform for high margin niche products, intended for use in specialized market segments. The Company has developed six proprietary platform technologies based on principles of biochemistry, immunochemistry, molecular biology, and/or electronics.

1. minDNA technology allows for the analysis of DNA in one minute using a hand-held reader, and has been applied in the development of the rapid white blood cell count and absolute neutrophil count assays that can monitor side effects of certain psychiatric and oncology drugs. Other applications of minDNA technology can result in tests necessary for the safety of the blood supply, specific identification of parasitic infections, and biowarfare agent detection.
2. Synthetic Macrocyclic technology is associated with the development of novel electronic readers that determine quantitative levels of therapeutic drugs, such as lithium blood levels. These hand-held readers and their associated proprietary reagents unlock new potential in both professional and consumer markets, particularly in therapeutic drug monitoring.
3. Rapid Enzymatic Assay technology focuses on the detection of blood and urine metabolites through enzymatic chemistries in quantitative or semi-quantitative formats. These products are primarily intended for pharmaceutical or nutritional markets, and include tests such as total and HDL cholesterol and testosterone.
4. Particle ImmunoFiltration Assay (PIFA) is a rapid immunoassay technology that has been developed into an extensive range of rapid testing products, including HIV, sexually-transmitted diseases, malaria, prostate cancer, blood typing, and chlamydia. These robust products produce results in minutes comparable to laboratory-based assays.
5. MicroParticle Catalyzed Biosensor (MPC Biosensor™) based products include breathalyzers, most notably the Company's alcohol breathalyzer, which is the only portable breathalyzer approved by the US Department of Transportation.
6. Biosniffer Continuous Monitoring Detector for Biowarfare Agents is designed to provide real-time information on the probable cause of an atmospheric release of biowarfare agents.

CLINICAL AREAS AND SELECT PRODUCTS

Cardiology/Emergency Medicine

Heparin/PF-4
Battlefield Blood Transfusion Card

Neuropsychiatry

White Blood Cell Count
Lithium

Metabolism/Nutrition

Cholesterol
Glucose
Alcohol Breathalyzer

Infectious Diseases / Bioagent Detection

Biowarfare Agents
HIV
STDs
Malaria
Blood-borne Pathogens

Oncology

PSA

BUSINESS STRATEGY

The Company's strategy is to target carefully chosen key markets where existing tests do not effectively fulfil clinical requirements. The tests are selected based on their ability to compliment a specific pharmaceutical product in one of three ways: 1) monitoring drug dosage levels; 2) detecting unwanted side effects of the drug; and 3) identifying appropriate candidates for therapy. The diagnostic test can thus increase the market penetration of the therapeutic agent. The Company has successfully used this strategy to forge strategic alliances with pharma, thus leveraging pharma's strengths in marketing, promotion, and access to customers.

ABI's sales and marketing strategy is based upon developing key strategic alliances with established pharma and medical products companies with strong distribution channels in its four key market segments:

- Biotech/Pharma Alliances
- Military/Government
- OTC/Physicians' Office
- Aid Organizations


SUMMARY

- ABI's proprietary platform technologies are adaptable to a wide range of applications, many with blockbuster potential.
- Unique products have received regulatory approvals and have been accepted by the marketplace.
- Key strategic alliances with pharma and medical products companies provide clear distribution channels.
- Low cost, scalable manufacturing provides high margin revenue.

BOARD OF DIRECTORS and OFFICERS

- **David Wilbraham BSc, Ph.D.**, Chairman, Non-executive Director
Non-executive Director of St. Ives plc, RPC Group plc and Intelligent Engineering Limited.
- **Thomas A. Nicolette**, President and Chief Executive Officer, *is past Chairman, President and Chief Executive Officer of several public companies in the USA. The largest, KNOGO Corporation, was a NYSE listed multinational headquartered on Long Island, NY with over 4000 employees in 42 countries.*
- **Raymond Akers, Jr., Ph.D.**, Executive Vice Chair, *Co-founder and inventor of PIFA®. Over 17 years experience in the diagnostics industry having co-founded Drug Screening, Inc. and Akers Medical Technology Inc.*
- **Edward Mulhare**, Non-executive Director
Previously Chairman of the Merrill Lynch Interfunding Group.
- **Daniel Seckinger, MD** Non-executive Director, *Currently President of The American Registry of Pathology and on the Board of The College of American Pathologist Foundation*

Akers Biosciences, Inc. is listed on the Alternative Investment Market of the London Stock Exchange under the ticker symbol: AKR.L.

 **Akers Biosciences**
Accelerating Diagnostic Science To Deliver Real-Time Results
201 Grove Road
Thorofare, New Jersey 08086 USA
Tel: + 856-848-8698

212 Piccadilly
London, W1J 9HG
UNITED KINGDOM
Tel: + 44 (0)20 7917 9476

Email: info@akersbiosciences.com

Website: www.akersbiosciences.com

Nominated Adviser & Broker

Arbuthnot Securities Ltd
Arbuthnot House
20 Ropemaker Street
London EC2Y 9AR
UNITED KINGDOM
Tel: +44 (0)20 7012 2000
<http://www.arbuthnotsecurities.co.uk/>

Investor Relations

Ben Simons
M Communications Limited
UNITED KINGDOM
Tel: +44 (0)20 7153 1530
Email: simons@mcomgroup.com
4/2008